[(1S,2R,5S,6S,16E,18E,20S,21S)-11-chloro-21-hydroxy-12,20-bis(hydroxymethyl)-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10(26),11,13,16,18-pentaen-6-yl] (2S)-2-[methyl-[6-(3-methyl-2,5-dioxopyrrolidin-1-yl)hexanoyl]amino]propanoate

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 大环内酰胺类
• 英文名称: [(1S,2R,5S,6S,16E,18E,20S,21S)-11-chloro-21-hydroxy-12,20-bis(hydroxymethyl)-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10(26),11,13,16,18-pentaen-6-yl] (2S)-2-[methyl-[6-(3-methyl-2,5-dioxopyrrolidin-1-yl)hexanoyl]amino]propanoate
• 化学式: C₄₃H₅₉ClN₄O₁₂
• 分子量: 859.4
• InChiKey: MIFGXQJMBXIFEA-AKGVLMJZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  60
• 可旋转键数：
  12
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.63
• 拓扑面积：
  216
• 氢给体数：
  4
• 氢受体数：
  12

文献信息

• COMPOUNDS AND METHODS FOR THE TREATMENT OF ERB B2/NEU POSITIVE DISEASES
  申请人：Bio-Thera Solutions, Ltd. Co.

  公开号：US20140178413A1

  公开（公告）日：2014-06-26

  Disclosed herein are anti-ERB B2/NEU antibodies conjugated with maytansinoid drugs for targeted delivery to disease tissues. Methods relating to the preparation and uses of such drug conjugates to treat ERB B2/NEU positive cells in cancers are provided.

  本文揭示了与马坦西诺伊德药物结合的抗ERB B2/NEU抗体，用于定向传递到疾病组织。提供了与制备和使用此类药物共轭物以治疗癌症中的ERB B2/NEU阳性细胞有关的方法。
• COMPOUNDS AND METHODS FOR THE TREATMENT OF CD20 POSITIVE DISEASES
  申请人：BIO-THERA SOLUTIONS, LTD., CO.

  公开号：US20140178411A1

  公开（公告）日：2014-06-26

  Disclosed herein are anti-CD20 antibody conjugated with maytansinoid drugs for targeted delivery to disease tissues. Methods related to the preparation and uses of such antibody drug conjugates to treat CD20 positive cells in cancers are provided.

  本文披露了与马替诺伊德药物结合的抗CD20抗体，用于靶向输送至疾病组织。提供了与制备和使用这种抗体药物结合物相关的方法，用于治疗癌症中的CD20阳性细胞。
• BISPECIFIC ANTIBODIES
  申请人：Bio-Thera Solutions, Ltd.

  公开号：US20150044216A1

  公开（公告）日：2015-02-12

  Provided are bispecific antibodies having a full-size antibody portion with two light chains and two heavy chains, wherein the two heavy chains each is fused to a single-chain variable fragment (scFv) portion. In certain embodiments, the full-size antibody has specificity to EGFR and the scFv has specificity to VEGF.

  提供的是具有完整抗体部分的双特异性抗体，其中包括两个轻链和两个重链，其中每个重链都与单链可变片段（scFv）部分融合。在某些实施例中，完整抗体具有对EGFR的特异性，而scFv具有对VEGF的特异性。
• US9314536B2
  申请人：——

  公开号：US9314536B2

  公开（公告）日：2016-04-19
• US9567403B2
  申请人：——

  公开号：US9567403B2

  公开（公告）日：2017-02-14